BRIEF-Absci Announces Positive Interim Phase 1 Data From The Headline™ Trial Of Abs-201, A Novel Antibody Targeting The Prolactin Receptor (Prlr)

Absci Corporation

Absci Corporation

ABSI

0.00

June 24 (Reuters) - Absci Corp ABSI.O:

  • ABSCI ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FROM THE HEADLINE™ TRIAL OF ABS-201, A NOVEL ANTIBODY TARGETING THE PROLACTIN RECEPTOR (PRLR)

  • ABSCI CORP - ABS-201 WELL TOLERATED WITH FAVORABLE SAFETY DATA IN ALL SAD COHORTS

  • ABSCI CORP - NO SERIOUS ADVERSE EVENTS REPORTED IN ABS-201 PHASE 1 INTERIM DATA

  • ABSCI CORP - INTERIM PROOF-OF-CONCEPT DATA FOR ABS-201 EXPECTED IN SECOND HALF OF 2026

  • ABSCI CORP - FIRST MULTIPLE ASCENDING DOSE COHORT OF ABS-201 INITIATED IN AGA PARTICIPANTS

  • ABSCI CORP - ABS-201 HALF-LIFE ESTIMATED AT LEAST 65 DAYS SUPPORTS INFREQUENT DOSING

  • ABSCI CORP: FULL PROOF-OF-CONCEPT DATA ANTICIPATED IN EARLY 2027

Source text: ID:nGNX2BgzPK

Further company coverage: ABSI.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.